Skip to content
value.today

Bio Green Med Solution, Inc.

BGMS
$6 Mmarket cap on Oct 26, 2026-51.6% since Jan 2024
Compare
World rank
#26,590
Revenue
$1 M
For year ending December-2025
Net income
$-3 M
-400.0% margin
SEC filing
Employees
19
As of December 31, 2025
value.today research

Bio Green Med Solution, Inc. in brief

Bio Green Med Solution, Inc. is a listed company in the Biotechnology industry, based in the USA. It was founded in 1997. Its market value was $6 M on 26 October 2026, which makes it the 26,590th largest listed company in the world and the 4,364th largest in the USA on this site. In the year to December 2025 it had sales of $1 M and a net loss of $3 M. It employs about 19 people. Its largest product and service lines by sales in 2025 were Product Revenue Fire Safety (100%), Fire Safety Equipment (81%) and Safety Aparel (16%). By market, the largest shares of its 2025 sales came from Malaysia (100%). Its shares trade under the symbol BGMS (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Bio Green Med Solution, Inc.

In December 2024, Bio Green Med Solution, Inc., a Delaware corporation formerly known as Cyclacel Pharmaceuticals, Inc., announced that it was in the process of exploring and reviewing strategic alternatives on an expedited basis in order to preserve the Company’s cash, including a potential transaction with investor, David E. Lazar of Activist Investing, LLC. On January 2, 2025, the Company entered into a securities purchase agreement with Lazar, pursuant to which he agreed to purchase from the Company, 1,000,000 shares of Series C Convertible Preferred Stock and 2,100,000 shares of Series D Convertible Preferred Stock of Cyclacel at a purchase price of $1.00 per share for aggregate gross proceeds of $3.1 million, subject to the terms and conditions of the securities purchase agreement. The proceeds of the transaction were used to settle outstanding liabilities of the Company and other general corporate and operating purposes.

Bio Green Med Solution, Inc. timeline

5 events, 1996–2025
  1. 1996
  2. 🏁
    · approximate
    Founded
  3. 2000
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2006
  6. ✎
    Renamed Cyclacel Pharmaceuticals, Inc.
    Formerly Xcyte Therapies Inc.
  7. 2025
  8. 💰
    Record revenue of $1 million
    FY2025, the highest of the 4 years on record.
  9. ✎
    Renamed Bio Green Med Solution, Inc.
    Formerly Cyclacel Pharmaceuticals, Inc..

Events of Bio Green Med Solution, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$8 M$15 M$23 M$30 M2020202120222023202420252026

World rank over time

▼ down 138 places since 2020
2020-01-01: #26459#26,45920202021-01-01: #24034#24,03420212022-01-07: #32907#32,90720222023-07-30: #28093#28,09320232024-01-05: #30392#30,39220242026-10-09: #26804#26,80420262026-10-26: #26597#26,5972026

Rank in USA: #4,672 (Jan 2020) · #4,518 (Jan 2021) · #5,587 (Jan 2022) · #5,045 (Jul 2023) · #4,463 (Jan 2024) · #4,343 (Oct 2026) · #4,367 (Oct 2026)

Key ratios

market cap and latest results
P/E ratio
n/m (loss)
Price / sales
8.4×
Price / book
0.9×
Free cash flow yield
-256.3%
Net margin
-400.0%
Operating margin
-1124.0%
Return on equity
-43.9%
Liabilities / assets
16.4%
Revenue growth
+1775.0%
R&D / revenue
113.3%
Revenue per employee
$39 K
Profit per employee
$-158 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $0M, net income $-7M$0MFY18Fiscal year ending Dec 2019: revenue —, net income $-8M—FY19Fiscal year ending Dec 2020: revenue —, net income $-8M—FY20Fiscal year ending Dec 2021: revenue —, net income $-18M—FY21Fiscal year ending Dec 2022: revenue —, net income $-21M—FY22Fiscal year ending Dec 2023: revenue $0M, net income $-23M$0MFY23Fiscal year ending Dec 2024: revenue $0M, net income $-11M$0MFY24Fiscal year ending Dec 2025: revenue $1M, net income $-3M$1MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$1M+1775.0%$-8M$-3M-400.0%
Dec 2024$0M-90.5%$-12M$-11M-28025.0%
Dec 2023$0M—$-25M$-23M-5371.4%
Dec 2022——$-28M$-21M—
Dec 2021——$-22M$-18M—
Dec 2020——$-11M$-8M—
Dec 2019——$-10M$-8M—
Dec 2018$0M—$-10M$-7M-4860.0%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-5M——$-6.45—
Dec 2024$-8M——$-502.46—
Dec 2023$-16M$0M$-16M$-6419.18—
Dec 2022$-21M$0M$-21M$-27.24—
Dec 2021$-19M$0M$-19M$-2.09—
Dec 2020$-8M$0M$-8M$-3.42—
Dec 2019$-9M$0M$-9M$-9.84—
Dec 2018$-7M$0M$-7M$-0.62—

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue —, net income $-3M—Dec ’24Three months to Mar 2025: revenue —, net income $-0M—Mar ’25Three months to Jun 2025: revenue —, net income $-1M—Jun ’25Three months to Sep 2025: revenue $0M, net income $-1M$0MSep ’25Three months to Dec 2025 (from the annual report): revenue —, net income $-1M—Dec ’25Three months to Mar 2026: revenue $1M, net income $-0M$1MMar ’26Three months to Jun 2026: revenue $0M, net income $-0M$0MJun ’26Three months to Sep 2026: revenue $0M, net income $-0M$0MSep ’26

Latest quarter to Sep 2026: revenue $0M (+462.5% on a year earlier), net income $-0M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Bio Green Med Solution, Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$1 M
Operating income
$-8 M
Net income
$-3 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$8 M
Total liabilities
$1 M
Total equity
$7 M

As of December-2025

Top 11 institutional investors in Bio Green Med Solution, Inc.#

As of Sep 30, 2026
11 institutions held 126,657 shares (about 1.9% of the shares outstanding) on Sep 30, 2026. The ten largest hold 1.9%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 11 largest institutional investors in Bio Green Med Solution, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Vanguard Fiduciary Trust Co55,704New0.84%$0 MNov 13, 2026
2Citadel Advisors LLC30,788-44,452 (-59.08%)0.46%$0 MNov 16, 2026
3XTX Topco Ltd24,337New0.37%$0 MNov 16, 2026
4Jane Street Group, LLC10,474-5,817 (-35.71%)0.16%$0 MNov 12, 2026
5Tower Research Capital LLC (TRC)4,567-1,155 (-20.19%)0.07%$0 MNov 16, 2026
6SBI Securities Co., Ltd.730+29 (+4.14%)0.01%$0 MOct 22, 2026
7UBS Group AG44-4,288 (-98.98%)0.00%$0 MNov 10, 2026
8Root Financial Partners, LLC7New0.00%$0 MOct 21, 2026
9Barclays PLC4New0.00%$0 MNov 6, 2026
10Citigroup Inc1New0.00%$0 MNov 4, 2026
11Archer Investment Corp1-1 (-50.00%)0.00%$0 MNov 5, 2026

Mutual funds holding Bio Green Med Solution, Inc.#

1 funds hold shares worth $0 M (about 0.2% of the company). Since their previous reports 1 added shares and 0 sold, buying $0 M net.
Mutual funds holding Bio Green Med Solution, Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC16,327$0 M0.25%<0.01%+828%May 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of May 31, 2026. The 1 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Bio Green Med Solution, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
24
since
$26 K-$4.7 M$0Dec 2023: bought $26 K (2 trades), sold $0 (0 trades)Dec 23Feb 2025: bought $0 (0 trades), sold $0 (1 trades)FebJul 2025: bought $0 (0 trades), sold $83 K (1 trades)JulSep 2025: bought $0 (0 trades), sold $400 K (3 trades)SepOct 2025: bought $0 (0 trades), sold $4.7 M (16 trades)OctNov 2025: bought $0 (0 trades), sold $49 K (1 trades)Nov
Bought (open market)Sold (open market)Hover a month for the totals
Bio Green Med Solution, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Cu Seng KiuChief Financial Officer, DirectorGrant or award+200,000$1.400$280 K200,000Form 4
filed Doris Wong Sing EeChief Executive Officer, Director, 10% ownerGrant or award+300,178$1.400$420 K1.11 MForm 4
filed Kim Choy Yap10% ownerSell-28,540$1.700$49 K0Form 4
filed Yee Lung Ong10% ownerOther+467,535——467,535Form 4
filed Khai Loon Kua10% ownerOther+467,535——467,535Form 4
filed Kim Choy Yap10% ownerOther+467,535——467,535Form 4
filed Yee Lung Ong10% ownerSell-248,814$1.800$448 K0Form 4
filed Khai Loon Kua10% ownerSell-242,477$1.800$436 K0Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Bio Green Med Solution, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
27,116
0.5% of shares · 1.17 days to cover
Shares sold short, last 24 reportsAll stocks →

Stock splits: 1-for-14.93 reverse split ; 1-for-20 reverse split

Trading halts

  • 2026-09-14 14:28 UTC, code LUDP, resumed 14:33 UTC
  • 2025-10-20 15:21 UTC, code LUDP, resumed 15:26 UTC
  • 2025-10-13 13:36 UTC, code LUDP, resumed 13:41 UTC
  • 2025-08-13 19:05 UTC, code LUDP, resumed 19:15 UTC
  • 2025-07-18 15:38 UTC, code LUDP, resumed 15:43 UTC

Fails to deliver

  • : 1,250 shares at $0.95
  • : 55 shares at $1.00
  • : 779 shares at $0.94
  • : 2,418 shares at $0.93
  • : 206 shares at $0.82

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Bio Green Med Solution, Inc. scorecard#

Passes 4 of the 12 checks that could be worked out: strongest in valuation (2 of 4), weakest in profitability (0 of 3). Fiscal year 2025; market cap of Oct 26, 2026.

  • Valuation2 of 4
    • ✗P/E below its peers' medianNo P/EThe company made a loss over the last twelve months.
    • ✓Price to book below its peers' median0.9×Price to book 0.9× against Biotechnology's median of 2.9×.
    • ✓Price to sales below its peers' median8.4×Price to sales 8.4× against Biotechnology's median of 8.7×.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • ✗Earnings yield above the 10-year Treasury yieldLossA loss earns nothing against the 10-year Treasury's 5.15% (2026-11-13).
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth1 of 2
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • ✗Earnings per share grew in the newest year-6.45 vs -502.46Diluted EPS -6.45 in fiscal 2025 against -502.46 the year before (report's currency).
    • ✓Net income higher than five years earlier-$3 M-$3 M in fiscal 2025 against -$8 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability0 of 3
    • ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • –Operating margin above its peers' medianNo operating margin on file.
    • ✗Return on equity above 15%-128.5%-128.5% in fiscal 2025.
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 3
    • ✓Short-term assets cover short-term liabilities4.7×Current ratio 4.71 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-77.54Z-score -77.54 (distress zone) for fiscal 2025.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Bio Green Med Solution, Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Bio Green Med Solution, Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue0.70.00.4000—0.200.8
Research and development0.86.7192015r4.84.74.34.29.5
Selling, general and administrative—5.46.77.47.55.95.05.45.35.5
General and administrative7.75.46.7———————
Operating expenses9.212262822——9.79.5—
Total costs and expenses———2823119.79.79.515
Operating income−8.4−12−25−28−22r−11−9.7−9.5−9.5−14
Interest and finance income—0.00.30.20.00.00.20.30.10.0
Net interest income0.10.0————————
Other non-operating income (expense)5.40.0−0.11.70.21.00.60.91.00.4
Income before tax−3.0−12−26−26−22r−9.7−9.1−8.6−8.5−14
Income tax0.0−0.8−3.0−4.7−3.7r−1.2−1.3−1.3−1.0−2.0
Net income including minority interests—−11−23—−18—————
Net income attributable to shareholders−3.0−11−23−21−18r−8.4−7.8−7.3−7.5−12
Earnings per share, basic-6.45-502.46r-6,419.18r-1.90-2.09r-3.42-9.84r-0.62-1.95-3.50
Earnings per share, diluted-6.45-502.46r-6,419.18r-27.24r-2.09r-3.42-9.84r-0.62-1.95-3.50
Shares, weighted average (basic)2.20.0r3.5r118.93.6————
Shares, weighted average (diluted)2.20.0r3.5r118.93.60.8r127.63.4
Balance sheet
Cash and cash equivalents3.53.13.418373312182417
Short-term investments———4.54.55.311172311
Receivables1.3————————0.0
Inventory1.4—————————
Other current assets0.10.3r0.30.4r0.10.10.10.2r0.1r0.0r
Current assets6.33.77.424413514202620
Property, plant and equipment0.10.00.00.00.10.10.00.00.00.0
Right-of-use (leased) assets0.00.00.10.10.01.21.3———
Goodwill1.6—————————
Total assets8.24.18.828r43r3715202620
Accounts payable0.64.63.52.62.10.50.92.71.62.5
Current liabilities1.36.38.27.5r5.4r2.52.44.54.15.3
Lease liabilities (non-current)0.000.00.10.01.11.2———
Total liabilities1.36.38.27.6r5.4r3.53.64.64.25.4
Retained earnings−454−439−428−406r−385r−366−358−350−343−335
Shareholders' equity6.8−2.20.616r38r3312152214
Total equity—−2.20.6———————
Total liabilities and equity8.24.18.828r43r3715202620
Shares outstanding5.40.0r0.0r0.6r10.06.20.9r12124.3
Cash-flow statement
Depreciation and amortization—————0.00.00.0r32r0.1
Share-based compensation2.30.61.51.51.20.40.50.30.30.8
Cash from operating activities−4.8−8.0−16−21−19−7.9−9.4−6.7−7.5−10
Capital expenditure——−0.0−0.0−0.0−0.1−0.0−0.0−0.0−0.0
Cash from investing activities——−0.0−0.0−0.0−0.10.0−0.0−0.00.0
Shares issued————4.0304.00.6156.8
Cash from financing activities5.37.80.83.022303.80.4156.6
Exchange-rate effect on cash————−0.00.0−0.0−0.1——
Change in cash0.4−0.2−15−183.222−5.6−6.47.4−3.9
Report10-K10-K10-K/A10-K10-K/A10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Bio Green Med Solution, Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Product Revenue Fire Safety$1 M100%
  • Fire Safety Equipment$1 M81%
  • Safety Aparel$0 M16%
  • Project Supply and Installation$0 M2.7%
  • Maintenance and Servicing$0 M0.8%

Business segments

  • Single Reportable$1 M100%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Where Bio Green Med Solution, Inc. operates: 2 countries#

Countries where the company has its headquarters, an office, subsidiaries, a branch or reported revenue.

Bio Green Med Solution, Inc.: countries of operation
CountryPresenceRevenue there
🇺🇸 USAHeadquarters1 office—
🇲🇾 Malaysia$1 M100%

Source: GLEIF legal-entity register, SEC Exhibit 21 and annual reports, office addresses on file. A country without subsidiaries or offices on record is not listed even if the company sells there. How presence is decided

Executive pay at Bio Green Med Solution, Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$847 K
Other top executives, average
$785 K
the CEO earned 1.1× this
$100 invested is now
$0
Bio Green Med Solution, Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Chief executive$847 K$847 K$785 K$0
2024Chief executive$585 K$548 K$364 K$4
2023Chief executive$661 K$66 K$833 K$27

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Bio Green Med Solution, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

Warning signs in the last three years

  • Delisting noticeFiling
  • Delisting noticeFiling
  • Delisting noticeFiling
  • Auditor changedFiling

Delisting notice 3 · Auditor changed 1 · Acquisition or sale completed 2 · Directors and officers 1 · Material agreement 7 · Unregistered share sale 3 · Shareholder rights changed 1 · Bylaws or fiscal year changed 2 · Shareholder vote 2 · Results announced 6

Bio Green Med Solution, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Delisting notice8-K
Results announced8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Delisting notice8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Acquisition or sale completedMaterial agreement8-K
Directors and officers8-K
Delisting notice8-K
Acquisition or sale completedShareholder rights changedBylaws or fiscal year changed8-K
Shareholder vote8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Auditor changed8-K
Results announced8-K
Bylaws or fiscal year changed8-K
Material agreement8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

1 private funding rounds before listing

Private share sales · funding history

Private share sales of Bio Green Med Solution, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Mar 2025$1 MPrivate placement after listingUnder $2 million4equitySEC
Nov 2024$2 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
May 2024$8 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Dec 2020$7 MPrivate placement after listing$2 to $10 million1equity, optionsSEC
Mar 2012$3 MPrivate placement after listing$2 to $10 million7equity, optionsSEC
Oct 2010$15 MNo. 1$10 to $50 million20equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Layoffs at Bio Green Med Solution, Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
0
2005–2005
Latest
—
2005-07-08
Bio Green Med Solution, Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2005············—
Bio Green Med Solution, Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
Not statedRestructuring planSEC 8-KCompany-wide planFiling
14% of workforceRestructuring planSEC 8-K“As a result of this more limited clinical development plan, the Company reduced its workforce by approximately 14%, from 83 to 71 employees, on May 17, 2005.”Filing
24% of workforceRestructuring planSEC 8-K“Item 2.05 Costs Associated with Exit or Disposal Activities As a result of the Registrant’s plan to limit clinical development primarily to the planned Phase II/III trial in CLL an…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Bio Green Med Solution, Inc. compares in Biotechnology

  • Market cap$6 M · higher than 7% of 726
  • Revenue$1 M · higher than 23% of 647
  • Net margin-400.0% · higher than 16% of 408
  • Revenue growth1775.0% · higher than 99% of 438
  • Price / sales8.4× · lower than 48% of 339
  • Price / book0.9× · lower than 81% of 534

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Bio Green Med Solution, Inc.🇺🇸$6 M—-400.0%+1775.0%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 26, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As of December 31, 2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Bio Green Med Solution, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Bio Green Med Solution, Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Bio Green Med Solution, Inc.? Suggest a correction